When was Ruichu Pharmaceutical founded?

Ruichu Pharmaceutical was founded in 2021 and raised its 1st funding round 3 years after it was founded.

Where is Ruichu Pharmaceutical located?

Ruichu Pharmaceutical is headquartered in Nanjing, China.

Is Ruichu Pharmaceutical a funded company?

Ruichu Pharmaceutical is a funded company, having raised a total of $***** in its 1st and only funding round, a Seed round on May 08, 2024.

When was the latest funding round of Ruichu Pharmaceutical?

Ruichu Pharmaceutical's latest funding was a $***** Seed round on May 08, 2024, with participation from 3 investors. Its primary sector is Immunology. In China, the Immunology sector has seen $324M in funding in 2026 to date.

Where does Ruichu Pharmaceutical rank among its competitors?

Ruichu Pharmaceutical ranks 26th amongst 74 active competitors, of which 27 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Tenpoint Therapeutics, which secured $85M in Jan, 2026.

Who are the top competitors of Ruichu Pharmaceutical?

Ruichu Pharmaceutical's top competitors include Skyhawk Therapeutics, Avalyn Pharma and Tenpoint Therapeutics. Among them, Tenpoint Therapeutics secured the most recent funding round in January, 2026.

Ruichu Pharmaceutical - 2026 Company Profile, Team, Funding & Competitors

Ruichu Pharmaceutical is a seed company based in Nanjing (China), founded in 2021 by Ji Yin. It operates as a Developer of therapeutics for aging-related diseases. Ruichu Pharmaceutical has raised an undisclosed amount in funding. The company has 74 active competitors, including 27 funded and 11 that have exited. Its top competitors include companies like Skyhawk Therapeutics, Avalyn Pharma and Tenpoint Therapeutics.

Company Details

Developer of therapeutics for aging-related diseases. The company focuses on the development of drugs to prevent, treat and reverse aging and aging-related diseases by targeting aging mechanisms to treat complex diseases such as ophthalmic diseases and fibrotic diseases.

Key Metrics

Founded Year

2021

Location

Nanjing, China

Stage

Seed

Latest Funding Round

Seed, May 08, 2024, $*****

Investors

Delian Capital & 2 more

Ranked

26^th among 74 active competitors

Similar Companies

Skyhawk Therapeutics & 79 more

View Ruichu Pharmaceutical's full profile

Ruichu Pharmaceutical has raised funding over 1 round. Its latest funding round was a Seed round on May 08, 2024 for $*****. 3 investors participated in its latest round. Ruichu Pharmaceutical has 3 institutional investors.

Here is the list of recent funding rounds of Ruichu Pharmaceutical:

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 08, 2024	8056941	Seed	9482132	7867914	3230099	8704755

Access funding benchmarks and valuations. Sign up today!

View details of Ruichu Pharmaceutical's funding rounds and investors

The founders of Ruichu Pharmaceutical is Ji Yin.

Here are the details of Ruichu Pharmaceutical's key team members:

Ji Yin: Founder of Ruichu Pharmaceutical.

View details of Ruichu Pharmaceutical's Founder profiles and Board Members

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Ruichu Pharmaceutical include Skyhawk Therapeutics, Avalyn Pharma and Tenpoint Therapeutics. Here is the list of Top 10 competitors of Ruichu Pharmaceutical, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Skyhawk Therapeutics 2017, Waltham (United States), Series B	Developer of RNA-modifying drug candidates for the treatment of multiple disorders	$181M	Alexandria, Fidelity Investments & 9 others	63/100
2nd	Avalyn Pharma 2011, Seattle (United States), Public	Developer of therapies for the treatment of Idiopathic Pulmonary Fibrosis	$389M	Perceptive Advisors, F-Prime Capital & 22 others	61/100
3rd	Tenpoint Therapeutics 2019, Warren (United States), Series B	Developer of engineered cell-based therapeutics to restore vision	$155M	EQT, Janus Henderson Investors & 20 others	61/100
4th	Sionna 2019, Natick (United States), Public	Developer of therapeutics to treat cystic fibrosis	$332M	Orbimed, Enavate Sciences & 7 others	60/100
5th	Alentis Therapeutics 2019, Basel (Switzerland), Series D	Developer of therapies for treating fibrosis, cirrhosis, and liver cancer	$366M	Novo Holdings, Jeito & 15 others	58/100
6th	Character Biosciences 2019, San Francisco (United States), Series B	Developer of therapeutics for the treatment of age-related eye diseases	$120M	Innovation Endeavors, aMoon & 12 others	57/100
7th	Mediar Therapeutics 2018, Cambridge (United States), Series B	Developer of antibody-based therapeutics for treating fibrosis	$181M	Amplitude, Novartis Venture Fund & 17 others	57/100
8th	PulseSight 2008, Paris (France), Series B	Developer of non-viral minimally invasive gene therapies for retinal diseases	$54.2M	ND Capital, Boehringer Ingelheim Venture Fund ... & 10 others	56/100
9th	Arcturus Therapeutics 2013, San Diego (United States), Public	Developer of RNAi technologies for the treatment of rare orphan diseases	$1.3M	Cystic Fibrosis Foundation, JLABS & 1 others	56/100
10th	Ashvattha Therapeutics 2015, Redwood City (United States), Series B	Developer of nanomedicines for ophthalmology, neurology, and inflammatory diseases	$120M	Tribe Capital, Natural Capital & 11 others	56/100
26th	Ruichu Pharmaceutical 2021, Nanjing (China), Seed	Developer of therapeutics for aging-related diseases	-	Delian Capital, Dingxin Capital & 1 others	37/100